(Q37814078)

23 August 2017

1 reference

title

Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis (English)

1 reference

23 August 2017

1 reference

3

Frank Buttgereit

0 references

author name string

Jos N Hoes

series ordinal

1

1 reference

23 August 2017

Johannes W G Jacobs

series ordinal

2

1 reference

23 August 2017

Johannes W J Bijlsma

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Nature Reviews Rheumatology

23 August 2017

1 reference

23 August 2017

6

1 reference

23 August 2017

693-702

1 reference

23 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2010.179

23 August 2017

0 references

cites work

A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Biologic agents-a panacea for inflammatory arthritis or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Optimised glucocorticoid therapy: the sharpening of an old spear

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Rheumatoid arthritis in the developing world

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

The links between joint damage and disability in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Effects of glucocorticoids on radiological progression in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Glucocorticoid resistance in inflammatory diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

How to perform local soft-tissue glucocorticoid injections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Is radiation synovectomy for arthritis of the knee more effective than intraarticular treatment with glucocorticoids? Results of an eighteen-month, randomized, double-blind, placebo-controlled, crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Systemic effects of intra-articular corticosteroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Bisphosphonates for steroid induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Prevention of chronic NSAID induced upper gastrointestinal toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Risk of infectious complications in patients taking glucocorticosteroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Genomic and nongenomic effects of glucocorticoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

EMPIRE Rheumatism Council: multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis; results of three years' treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.179

A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. A second report by the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other t

31 March 2020

1 reference

12 December 2020

Low dose prednisolone for treatment of RA.

1 reference

12 December 2020

Low dose prednisone therapy in rheumatoid arthritis: a double blind study

1 reference

12 December 2020

Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms

1 reference

12 December 2020

Inpatient treatment of rheumatoid arthritis with synacthen depot: a double blind placebo controlled trial with 6 month followup

1 reference

12 December 2020

Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.

1 reference

12 December 2020

Effect of small-dose glucocorticoids on the course of early rheumatic arthritis

1 reference

12 December 2020

Effects of cortisone in the rheumatic diseases.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2010.179

1 reference

Dimensions Publication ID

23 August 2017

0 references

1 reference